Browse Studies — Arctuva

Phase 1

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

Estimated

~$10 – $7,500

Anusha KalbasiNCT04119024

Phase 1

A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas

This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab in tre…

Advanced AdenocarcinomaAdvanced Malignant Solid NeoplasmMetastatic Adenocarcinoma+3 more

Estimated

~$10 – $7,500

Tianhong LiNCT05101356

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer…

Hematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+1 more

Estimated

~$10 – $675

National Cancer Institute LAONCT02474160

Phase 1

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolesc…

Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm+6 more

Estimated

~$10 – $7,500

Children's Oncology GroupNCT06620302